A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. (MACURELI)

Pfizer

Status: Completed

Conditions: Neovascular Age-related Macular Degeneration

Treatments: Drug: Macugen

Study type: Observational

Funder types: Industry

Identifiers

NCT00549055

A5751026

Details and patient eligibility

About

To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity. Treatment duration, frequency of administration and combination with other treatments will also be evaluated.

Enrollment: 38 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with subfoveal neovascular (wet) age-related macular degeneration
• Patients having received at least 1 Macugen injection
• Treatment naive patients, or patients having received conventional therapy
• Patients having signed and dated informed consent.

Exclusion criteria

• Patients participating in another clinical study with Macugen.

Trial design

38 participants in 1 patient group

1

Description:

Patients who obtained reimbursement of Macugen.

Treatment:

Drug: Macugen